PL3291831T3 - Rekombinowana mykobakteria jako środek immunoterapeutyczny do leczenia nowotworu - Google Patents

Rekombinowana mykobakteria jako środek immunoterapeutyczny do leczenia nowotworu

Info

Publication number
PL3291831T3
PL3291831T3 PL16724315T PL16724315T PL3291831T3 PL 3291831 T3 PL3291831 T3 PL 3291831T3 PL 16724315 T PL16724315 T PL 16724315T PL 16724315 T PL16724315 T PL 16724315T PL 3291831 T3 PL3291831 T3 PL 3291831T3
Authority
PL
Poland
Prior art keywords
mycobacteria
immunotherapy
recombined
cancer
treatment
Prior art date
Application number
PL16724315T
Other languages
English (en)
Inventor
Leander Grode
Original Assignee
Vakzine Projekt Management Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Management Gmbh filed Critical Vakzine Projekt Management Gmbh
Publication of PL3291831T3 publication Critical patent/PL3291831T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34Antigenic peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45Bacterial antigens
    • A61K40/4524Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01005Urease (3.5.1.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL16724315T 2015-05-04 2016-05-03 Rekombinowana mykobakteria jako środek immunoterapeutyczny do leczenia nowotworu PL3291831T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15166206.1A EP3090757A1 (en) 2015-05-04 2015-05-04 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US201562387407P 2015-12-23 2015-12-23
PCT/EP2016/059872 WO2016177717A1 (en) 2015-05-04 2016-05-03 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP16724315.3A EP3291831B1 (en) 2015-05-04 2016-05-03 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL3291831T3 true PL3291831T3 (pl) 2021-05-31

Family

ID=53054880

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16724315T PL3291831T3 (pl) 2015-05-04 2016-05-03 Rekombinowana mykobakteria jako środek immunoterapeutyczny do leczenia nowotworu

Country Status (24)

Country Link
US (2) US10525118B2 (pl)
EP (2) EP3090757A1 (pl)
JP (1) JP6778697B2 (pl)
KR (1) KR102667859B1 (pl)
CN (1) CN107864656A (pl)
AU (1) AU2016258885B2 (pl)
BR (1) BR112017023747A2 (pl)
CA (1) CA2984602C (pl)
CU (1) CU20170138A7 (pl)
CY (1) CY1123754T1 (pl)
DK (1) DK3291831T3 (pl)
EA (1) EA036492B1 (pl)
ES (1) ES2845724T3 (pl)
HR (1) HRP20210107T1 (pl)
HU (1) HUE052711T2 (pl)
IL (1) IL255303B (pl)
LT (1) LT3291831T (pl)
MX (1) MX389038B (pl)
PH (1) PH12017502011A1 (pl)
PL (1) PL3291831T3 (pl)
PT (1) PT3291831T (pl)
RS (1) RS61333B1 (pl)
SI (1) SI3291831T1 (pl)
WO (1) WO2016177717A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117098848A (zh) * 2021-03-22 2023-11-21 科列普斯生物医药科技有限公司 新型耻垢分枝杆菌重组菌株及其应用
KR20240082332A (ko) * 2021-07-22 2024-06-10 세럼 라이프 사이언스 유럽 게엠베하 방광암종의 2차 치료를 위한 면역치료제로서의 재조합 마이코박테리움
US20240277825A1 (en) * 2021-07-22 2024-08-22 Serum Life Science Europe Gmbh Recombinant Mycobacterium as an Immunotherapeutic Agent for the Second-Line Therapy of Bladder Carcinoma
EP4122491A1 (en) * 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733151A (en) 1996-08-23 1998-03-31 Edsall; David Electrical clamping connection device
WO2004094469A1 (en) * 2003-04-23 2004-11-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine with improved efficacy
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
AU2014210617B2 (en) * 2004-10-21 2016-07-21 Vakzine Projekt Management Gmbh Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
DK3360569T3 (da) * 2010-09-20 2020-04-06 Vakzine Projekt Man Gmbh Rekombinant mykobakterie som vaccine til anvendelse på mennesker
EP2654783B1 (en) * 2010-12-21 2016-10-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant mycobacterium as a vaccine
US9678075B2 (en) * 2011-06-10 2017-06-13 Deutsches Krebsforschungszentrum Prediction of recurrence for bladder cancer by a protein signature in tissue samples
EP2620159A1 (en) * 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria

Also Published As

Publication number Publication date
US20180200357A1 (en) 2018-07-19
EA201792412A1 (ru) 2018-03-30
EP3291831A1 (en) 2018-03-14
HUE052711T2 (hu) 2021-05-28
US11426453B2 (en) 2022-08-30
EP3291831B1 (en) 2020-12-30
JP6778697B2 (ja) 2020-11-04
CN107864656A (zh) 2018-03-30
CY1123754T1 (el) 2022-05-27
PH12017502011A1 (en) 2018-03-26
IL255303B (en) 2021-08-31
DK3291831T3 (da) 2021-01-18
WO2016177717A1 (en) 2016-11-10
HK1247574A1 (en) 2018-09-28
KR102667859B1 (ko) 2024-05-21
CU20170138A7 (es) 2018-04-03
US20200179502A1 (en) 2020-06-11
RS61333B1 (sr) 2021-02-26
AU2016258885B2 (en) 2021-12-09
LT3291831T (lt) 2021-02-25
IL255303A0 (en) 2017-12-31
PT3291831T (pt) 2021-01-26
AU2016258885A1 (en) 2017-11-23
US10525118B2 (en) 2020-01-07
MX389038B (es) 2025-03-20
HRP20210107T1 (hr) 2021-03-19
KR20170140328A (ko) 2017-12-20
EA036492B1 (ru) 2020-11-17
JP2018520643A (ja) 2018-08-02
CA2984602C (en) 2023-09-05
CA2984602A1 (en) 2016-11-10
EP3090757A1 (en) 2016-11-09
MX2017014142A (es) 2018-03-15
ES2845724T3 (es) 2021-07-27
BR112017023747A2 (pt) 2018-07-31
SI3291831T1 (sl) 2021-03-31

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL269810A (en) Combinatorial cancer immunotherapy
EP3402517A4 (en) Immunologic treatment of cancer
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
IL255261A0 (en) Methods for treating cancer
PL3288581T3 (pl) Sposób leczenia nowotworu
DK3594238T3 (da) Antistofsammensætninger til tumorbehandling
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
IL249065A0 (en) Combination therapies for the treatment of cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
HUE059694T2 (hu) Készítmény rák kezelésére
SI3240801T1 (sl) Kombinirana imunoterapija tumorja
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
IL285077A (en) Compounds for the treatment of cancer
HUE038541T2 (hu) Rák kezelési módszerek
EP3360010A4 (en) BI PHOTONS WITH VOTABLE SOURCE
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
PL3393468T3 (pl) Metody leczenia niedoboru odporności
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
IL246558A0 (en) Novel methods for treating cancer
SG10202007893TA (en) Methods of immunotherapy